Home » Stocks » Unum Therapeutics

Unum Therapeutics Inc. (UMRX)

Stock Price: $0.440 USD -0.030 (-6.38%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 13.71M
Revenue (ttm) 26.48M
Net Income (ttm) -26.24M
Shares Out 31.16M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $0.440
Previous Close $0.470
Change ($) -0.030
Change (%) -6.38%
Day's Open 0.480
Day's Range 0.430 - 0.480
Day's Volume 359,076
52-Week Range 0.295 - 2.840

More Stats

Market Cap 13.71M
Enterprise Value n/a
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.16M
Float 14.97M
EPS (basic) -0.85
EPS (diluted) -0.86
FCF / Share -1.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 397,541
Short Ratio 0.72
Short % of Float 2.32%
Beta 1.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.52
PB Ratio 0.59
Revenue 26.48M
Operating Income -26.48M
Net Income -26.24M
Free Cash Flow -37.68M
Net Cash 25.21M
Net Cash / Share 0.81
Gross Margin -80.11%
Operating Margin -100.00%
Profit Margin -99.10%
FCF Margin -142.30%
ROA -25.76%
ROE -69.97%
ROIC 2,281.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$1.00*
Low
1.00
Current: 0.440
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue22.509.738.366.362.99
Revenue Growth131.14%16.44%31.55%112.83%-
Gross Profit22.509.738.366.362.99
Operating Income-32.18-36.01-26.15-19.07-6.59
Net Income-31.83-34.53-25.49-18.12-6.59
Shares Outstanding30.4824.9010.1910.1910.19
Earnings Per Share-1.04-1.39-2.51-1.78-0.65
Operating Cash Flow-41.51-32.49-25.84-18.6417.72
Capital Expenditures0.17-0.55-0.91-3.31-1.99
Free Cash Flow-41.34-33.04-26.75-21.9515.72
Cash & Equivalents38.6879.8542.2969.760.00
Total Debt6.03----
Net Cash / Debt32.6579.8542.2969.760.00
Assets49.4285.9349.1275.55-
Liabilities17.6625.6920.8123.16-
Book Value31.7660.23-48.85-24.70-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Unum Therapeutics Inc.
Country United States
Employees 29
CEO Charles Wilson

Stock Information

Ticker Symbol UMRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: UMRX
IPO Date March 29, 2018

Description

Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.